Medicare Enrolled
Dr. Ari Baron, M.D.
Optician · San Francisco, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Baron from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Baron?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Baron
Dr. Ari Baron is an optician specialist in San Francisco, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Baron performed 86,974 Medicare services across 2,240 unique beneficiaries.
Between the years covered by Open Payments, Dr. Baron received a total of $789,066 from 91 pharmaceutical and/or device companies across 1295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Baron is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in CA
$789,066 industry payments
Medicare Practice Summary
Medicare Utilization ↗86,974
Medicare services
Top 1% in CA for optician
2,240
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,578 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
24,990 | $0 | $11 |
| Pembrolizumab injection (Keytruda) | 10,625 | $43 | $114 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
10,379 | $2 | $15 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
8,113 | $0 | $25 |
| Denosumab injection (Prolia/Xgeva) | 6,946 | $18 | $54 |
| Nivolumab injection (Opdivo) | 6,309 | $23 | $63 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,723 | $0 | $13 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,075 | $0 | $17 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,609 | $1 | $45 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
949 | $8 | $26 |
| Injection, leucovorin calcium, per 50 mg | 934 | $3 | $41 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
874 | $22 | $207 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
778 | $108 | $263 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
710 | $73 | $708 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
640 | $2 | $12 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
599 | $136 | $499 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
486 | $13 | $55 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 363 | $2 | $219 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
343 | $16 | $75 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
319 | $156 | $352 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
235 | $67 | $240 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
222 | $29 | $114 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
204 | $29 | $110 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 171 | $69 | $605 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
137 | $33 | $140 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
132 | $2 | $159 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
126 | $19 | $55 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
110 | $86 | $352 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
106 | $1 | $10 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
77 | $57 | $203 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
75 | $74 | $174 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
71 | $70 | $148 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
70 | $136 | $424 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
56 | $1 | $10 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
52 | $36 | $168 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
48 | $26 | $63 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
45 | $145 | $400 |
| New patient office visit, complex (60-74 min) | 42 | $193 | $498 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
42 | $1 | $16 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
34 | $34 | $180 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
34 | $20 | $62 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
33 | $105 | $211 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
28 | $2 | $20 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
24 | $67 | $245 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
19 | $154 | $403 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
17 | $27 | $112 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.1% high complexity
66.8% medium
3.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$789,066
Total received (2018-2024)
Avg $112,724/year across 7 years
Top 1% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
91
Companies
1,295
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$764,903 (96.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$15,818 (2.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,346 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$49,173
2023
$109,130
2022
$114,495
2021
$101,933
2020
$53,805
2019
$194,278
2018
$166,252
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$19,836
Bayer Healthcare Pharmaceuticals Inc.
$14,599
ABBVIE INC.
$13,113
Merck Sharp & Dohme LLC
$126
Gilead Sciences, Inc.
$100
PFIZER INC.
$95
AstraZeneca Pharmaceuticals LP
$91
Takeda Pharmaceuticals U.S.A., Inc.
$90
Novartis Pharmaceuticals Corporation
$84
Astellas Pharma US Inc
$63
Blueprint Medicines Corporation
$61
GlaxoSmithKline, LLC.
$57
Genentech USA, Inc.
$53
Alexion Pharmaceuticals, Inc.
$53
GENZYME CORPORATION
$52
Incyte Corporation
$50
Rigel Pharmaceuticals, Inc.
$46
SERVIER PHARMACEUTICALS LLC
$44
Regeneron Healthcare Solutions, Inc.
$43
Daiichi Sankyo Inc.
$42
Eisai Inc.
$38
Exelixis Inc.
$36
SpringWorks Therapeutics, Inc.
$35
Coherus Biosciences Inc.
$34
Karyopharm Therapeutics Inc.
$31
PUMA BIOTECHNOLOGY, INC.
$29
PharmaEssentia USA Corporation
$29
ADC Therapeutics America, Inc.
$28
Deciphera Pharmaceuticals Inc.
$28
Lilly USA, LLC
$26
Mirati Therapeutics, Inc.
$23
Myriad Genetic Laboratories, Inc.
$23
Apellis Pharmaceuticals, Inc.
$22
Celgene Corporation
$21
Secura Bio, Inc.
$20
Janssen Biotech, Inc.
$18
Acrotech Biopharma Inc.
$18
Pharmacosmos Therapeutics Inc.
$17
Top 3 companies account for 96.7% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$290,709
Lilly USA, LLC
$142,867
Amgen Inc.
$43,311
Exelixis Inc.
$41,146
Janssen Biotech, Inc.
$33,261
AbbVie, Inc.
$31,067
Bayer HealthCare Pharmaceuticals Inc.
$23,537
Bayer Healthcare Pharmaceuticals Inc.
$22,622
Taiho Oncology, Inc.
$21,266
Eisai Inc.
$19,035
Merck Sharp & Dohme Corporation
$18,399
EISAI INC.
$17,222
ABBVIE INC.
$16,421
AbbVie Inc.
$14,091
Astellas Pharma US Inc
$12,975
Janssen Scientific Affairs, LLC
$10,279
PFIZER INC.
$7,182
Genentech USA, Inc.
$6,836
G1 Therapeutics, Inc.
$2,269
Celgene Corporation
$2,259
Helsinn Therapeutics (U.S.), Inc.
$1,984
AstraZeneca Pharmaceuticals LP
$1,875
AstraZeneca UK Limited
$1,370
Deciphera Pharmaceuticals Inc.
$869
Novartis Pharmaceuticals Corporation
$322
Octapharma USA, Inc.
$313
GlaxoSmithKline, LLC.
$299
Merck Sharp & Dohme LLC
$297
Takeda Pharmaceuticals U.S.A., Inc.
$289
GENZYME CORPORATION
$241
Pharmacyclics LLC, an AbbVie Company
$236
Sirtex Medical Inc
$230
Gilead Sciences, Inc.
$221
Pharmacyclics LLC, An AbbVie Company
$216
Incyte Corporation
$214
Alexion Pharmaceuticals, Inc.
$184
Seagen Inc.
$180
Blueprint Medicines Corporation
$140
Rigel Pharmaceuticals, Inc.
$136
Daiichi Sankyo Inc.
$130
Spectrum Pharmaceuticals Inc.
$127
Regeneron Healthcare Solutions, Inc.
$110
ADC Therapeutics America, Inc.
$100
Karyopharm Therapeutics Inc.
$90
SERVIER PHARMACEUTICALS LLC
$88
PharmaEssentia USA Corporation
$85
Servier Pharmaceuticals LLC
$85
Jazz Pharmaceuticals Inc.
$84
Janssen Pharmaceuticals, Inc
$81
Pharmacosmos Therapeutics Inc.
$80
Clovis Oncology, Inc.
$73
Coherus Biosciences Inc.
$73
Boehringer Ingelheim Pharmaceuticals, Inc.
$67
Seattle Genetics, Inc.
$67
SANOFI-AVENTIS U.S. LLC
$60
Secura Bio, Inc.
$60
PUMA BIOTECHNOLOGY, INC.
$59
EMD Serono, Inc.
$59
AVEO Pharmaceuticals, Inc.
$55
Kyowa Kirin, Inc.
$54
NOVARTIS PHARMACEUTICALS CORPORATION
$50
SOBI, INC
$50
Acrotech Biopharma LLC
$47
Kite Pharma, Inc.
$46
Mirati Therapeutics, Inc.
$46
Heron Therapeutics, Inc.
$45
Epizyme, Inc.,
$43
Puma Biotechnology, Inc.
$42
Apellis Pharmaceuticals, Inc.
$42
Dova Pharmaceuticals
$40
Myriad Genetic Laboratories, Inc.
$40
Genentech, Inc.
$39
AMAG Pharmaceuticals, Inc.
$38
Agios Pharmaceuticals, Inc.
$38
SpringWorks Therapeutics, Inc.
$35
Acrotech Biopharma Inc.
$34
JAZZ PHARMACEUTICALS INC.
$33
TESARO, Inc.
$33
BeiGene USA, Inc.
$27
CTI BioPharma Corp.
$25
Ipsen Biopharmaceuticals, Inc
$25
MorphoSys, US Inc.
$23
TAIHO ONCOLOGY, INC.
$23
Allergan, Inc.
$22
ARRAY BIOPHARMA INC
$22
Mylan Institutional Inc.
$20
Sobi, Inc
$18
Array BioPharma Inc.
$17
Aurobindo Pharma USA, Inc.
$15
Teva Pharmaceuticals USA, Inc.
$14
Verastem, Inc.
$14
Top 3 companies account for 60.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · Aranesp · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Beleodaq · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CAMZYOS · CEREZYME · CINVANTI · COPIKTRA · COSELA · CREON · CYRAMZA · Cabometyx · Cabozantinib · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Enhertu · Erleada · FARESTON · FERAHEME · FOLOTYN · FOTIVDA · FRUZAQLA · Fabhalta · Folotyn · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JAYPIRCA · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONCASPAR · OPDIVO · OPDUALAG · Ogivri · Oncaspar · PADCEV · PANZYGA · PIQRAY · POTELIGEO · PRECISETUMOR · PROMACTA · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TRUSELTIQ · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VYXEOS · Venclexta · Vonjo · Voranigo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · ZALTRAP · ZEJULA · ZENPEP · ZEPZELCA · ZYKADIA · ZYTIGA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (97%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in optician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for optician in CA.
Geographic Context
Opticians within 10 mi
1,298
Per 100K population
155.2
County median income
$141,446
Nearest hospital
KAISER FOUNDATION HOSPITAL - SAN FRANCISCO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Baron is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with speaking/promotional industry engagement in the top 1% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Baron experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Baron performed 24,990 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Baron receive payments from pharmaceutical companies?
Yes. Dr. Baron received a total of $789,066 from 91 companies across 1,295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Baron's costs compare to other opticians in San Francisco?
Dr. Baron's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Baron) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in San Francisco
Browse opticians in San Francisco ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology